plerixafor + plerixafor + plerixafor
Phase 1/2Completed 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ewing's Sarcoma/Soft Tissue Sarcoma
Conditions
Ewing's Sarcoma/Soft Tissue Sarcoma, Neuroblastoma, Brain Tumors
Trial Timeline
Mar 3, 2014 → May 9, 2017
NCT ID
NCT01288573About plerixafor + plerixafor + plerixafor
plerixafor + plerixafor + plerixafor is a phase 1/2 stage product being developed by Sanofi for Ewing's Sarcoma/Soft Tissue Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01288573. Target conditions include Ewing's Sarcoma/Soft Tissue Sarcoma, Neuroblastoma, Brain Tumors.
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01288573 | Phase 1/2 | Completed |
Competing Products
3 competing products in Ewing's Sarcoma/Soft Tissue Sarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) | Eli Lilly | Phase 2 | 35 |
| CP-751,871 | Pfizer | Phase 1 | 29 |
| CP-751,871 | Pfizer | Phase 1/2 | 32 |